WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2011140337) STAPHYLOCOCCUS AUREUS LEUKOCIDINS, THERAPEUTIC COMPOSITIONS, AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2011/140337    International Application No.:    PCT/US2011/035354
Publication Date: 10.11.2011 International Filing Date: 05.05.2011
IPC:
A61K 39/395 (2006.01), A61K 38/16 (2006.01), A61K 38/17 (2006.01), A61P 17/00 (2006.01)
Applicants: NEW YORK UNIVERSITY [US/US]; 70 Washington Square South New York, New York 10012 (US) (For All Designated States Except US).
TORRES, Victor, J. [US/US]; (US) (For US Only).
DUMONT, Ashley, L. [US/US]; (US) (For US Only)
Inventors: TORRES, Victor, J.; (US).
DUMONT, Ashley, L.; (US)
Agent: FOLEY, Shawn, P.; Lerner, David, Littenberg, Krumholz & Mentlik, LLP 600 South Avenue West Westfield, NJ 07090 (US)
Priority Data:
61/331,550 05.05.2010 US
Title (EN) STAPHYLOCOCCUS AUREUS LEUKOCIDINS, THERAPEUTIC COMPOSITIONS, AND USES THEREOF
(FR) LEUCOCIDINES DE STAPHYLOCOCCUS AUREUS, COMPOSITIONS THÉRAPEUTIQUES ET LEURS UTILISATIONS
Abstract: front page image
(EN)Disclosed herein are isolated and purified Staphylococcus aureus bi-component leukocidin, referred to herein as LukAB, and its components LukA and LukB, antibodies specific to LukA, antibodies specific to LukB, therapeutic compositions containing LukA and/or LukB, or anti -LukA and/or anti-LukB antibodies, uses of the compositions to treat acute inflammatory conditions or S. aureus infection, methods for identifying inhibitors of LukAB-mediated cytotoxicity of human phagocytes, and methods for using LukAB as a marker to predict severity of S. aureus infection.
(FR)La présente invention concerne une leucocidine bi-composant isolée et purifiée de Staphylococcus aureus, désignée ici sous le nom de LukAB, ainsi que ses composants LukA et LukB, des anticorps spécifiques de LukA, des anticorps spécifiques de LukB, des compositions thérapeutiques contenant LukA et/ou LukB, ou des anticorps anti-LukA et/ou anti-LukB, les utilisations de ces compositions pour traiter des affections inflammatoires aiguës ou une infection par S. aureus, des méthodes d'identification d'inhibiteurs de la cytotoxicité à médiation par LukAB des phagocytes humains et des méthodes d'utilisation de LukAB en tant que marqueur de prédiction de la gravité d'une infection par S. aureus.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)